USPTO serial 79066457
BISULFITOME
Reviewed by CopyMark Law Group
Reg. 3828435Status 706Registered
- Filing date
- Status date
- Registration date
- Aug 3, 2010
- Examiner
- ROSSMAN, WILLIAM M
- Law office
- GENERIC WEB UPDATE
What this means
This trademark is registered with the USPTO. Monitoring new filings can help you catch lookalike marks early.
Need help with BISULFITOME?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Hilden, DE
Qiagenstraße 1; 40724 Hilden, DE
Qiagenstraße 1; 40724 Hilden, DE
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Victoria Friedman
Victoria Friedman Dennemeyer & Associates, LLC2 North Riverside Plaza, Suite 1500Chicago, IL 60606UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Chemical, biochemical and biotechnological products for scientific and laboratory research purposes, namely, nucleic acids, enzymes and polymererases for laboratory and research use, [ diagnostic reagents and chemical buffers used for the isolation, purification or separation of nucleic acids, oligonucleotides or proteins, and protein arrays none of the foregoing for medical or veterinary purposes; ] chemical reagents [ and aromatic solvents ] for [ sample preparation, modification and manipulation of cells and for conducting marking, separating, isolating, purifying, ] amplification and/or analytic methods for natural and synthetic biopolymers, namely, nucleic acids, oligonucleotides, [ protein, ] macromolecules and biologically active substances in the nature of nucleic acids; kits comprised of chemical, biochemical and biotechnological products for [ sample preparation, purification, modification and manipulation of cells as well as for ] the performance of [ marking, separation, isolation, purification, ] amplification and analysis of biopolymers, namely, kits comprised of nucleic acids, enzymes, [ proteins, macromolecules and biologically active substances in the nature of nucleic acids from biological and biochemical sample material; ] all for scientific or laboratory research purposes | ACTIVE | — |
| 005 | [ Pharmaceutical and veterinary preparations for medical use including studies and research and development purposes, namely, nucleic acids sequences, chemical reagents and biochemical preparations; diagnostic preparations for medical purposes; diagnostic preparations for medical and veterinary purposes, namely, diagnostic preparations for sample preparation, modification and manipulation of samples and cells and diagnostic preparations for marking, separating, isolating, purifying, amplification and/or medical and veterinary analysis of biopolymers, in the nature of nucleic acids sequences, oligo-nucleotide arrays, probes, primers, aptamers, antisense-oligonucleotides, promoters, microRNA (miRNA), ribozymes; chemical, biochemical and biotechnological preparations for medical use, namely, medical and veterinary diagnostic reagents and solvents for medical and veterinary use for sample preparation, modification and manipulation of samples and cells and medical and for conducting marking, separating, isolating, purifying, amplifying and/or analysis of biopolymers, in the nature of nucleic acid sequences, protein arrays, macromolecules and biologically effective substances in the nature of nucleic acid sequences all for diagnostic medical purposes; in vitro diagnostics reagents for medical purposes; kits comprising diagnostic preparations for medical or veterinary diagnostic purposes, namely, for medical and veterinary sample preparation, modification and manipulation of cells and for marking, separating, isolating, purifying, amplification and/or for the analysis of biopolymers, in the nature of nucleic acid sequences, oligo-nucleotide arrays, probes, primers, aptamers, antisense-oligonucleotides, promoters, microRNA (miRNA), ribozymes, proteins, macromolecules and biologically effective substances in the nature of nucleic acid sequences from biological and biochemical sample materials; all-purpose disinfectants ] | SECTION 71 - CANCELLED | — |
| 009 | [ Scientific apparatuses, instruments and devices for the purpose of surveying, weighing, measuring, signaling and regulating apparatuses, instruments and devices for research, laboratory and scientific purposes, namely, disposable bottle liners for use with laboratory apparatus; disposable and re-useable dispenser syringes for laboratory use; scales, plastic sample storage, reaction and collection vessels, namely, plates and multi-well plates that can be used in chemical analysis, biological analysis or patterning for scientific, laboratory or medical research use; laboratory consumables, namely, pipette tips, filter tips and dispenser tips, pipette tips and carrying pipette tip boxes; laboratory storage tubes, namely, test tubes, micro tubes and tubes for Polymerase Chain Reaction (PCR); micro-laboratory centrifuges and laboratory micro-injectors; laboratory equipment namely, cuvettes, spin columns, chromatography columns and cartridges filled with chromatographic materials for the purpose of separation, purification and isolation of biopolymers, nucleic acids, oligonucleotides, proteins, macromolecules and biologically active substances in the nature of nucleic acids from biological and biochemical sample materials for scientific or laboratory use; racks and holders for sample laboratory storage tubes and beakers, tubes, syringes and pipette tips; scientific instrument used in laboratory sample preparation, namely, magnetic beads for magnetic particle separation and handling and analyzing nucleic acids, proteins, enzymes, and chemicals; laboratory filters, namely, filter membranes for biotechnological and scientific purposes, namely, filter membranes and filter devices comprised of laboratory spin columns, tubes, plates, silica materials and filter strips in a microtitration format for the isolation and purification of nucleic acids and oligonucleotides, and other biological materials for laboratory and scientific use; sample presentation devices, namely, laboratory research micro-arrays, silicon chips, and Matrix-Assisted Laser Desorption/Ionization (MALDI) presentation device, namely, laser desorption plates for analyzing, diagnosing and presenting data in the field of spectrometry all used for laboratory or medical research; laboratory robots and robotic workstations comprising computer hardware for laboratory robots; laboratory incubators for diagnostic, clinical and research applications for the preparation, modification, isolation, crystallization, handling, amplification and manipulation of samples and for the marking, separation, isolation, purification, reproduction and analysis of biopolymers, nucleic acids, oligonucleotides, proteins, macromolecules and biologically active substances from sample material; laboratory apparatus and equipment, namely, computer hardware and software for dosage, dispensing, transferring, temperature equalizing, agitating, mixing, diluting, concentrating and separating of liquids; laboratory apparatus, namely, MALDI laser desorption plates for use in analytical analysis, medical, diagnostic and research workstations comprised of computer hardware and software for reading and handling multi-well plates for the analysis of biopolymers, nucleic acids, oligonucleotides, proteins, macromolecules and biologically active substances from sample materials; laboratory equipment, namely, thermal cyclers and cell disrupters; physico-chemical, biochemical, optical and electronic analysis apparatuses and equipment, namely, photometers, spectrophotometers, optical scanners for detection of fluorescence and colorimetric signals; apparatuses and instruments for processing cells or liquids containing cells namely, electroporators, micro-injectors and micro-manipulators; scientific apparatus, namely, ultra high vacuum chambers for chromatography, purification, separation and characterization of natural and synthetic biopolymers, nucleic acids, oligo-nucleotides, proteins, macromolecules and biologically active substances from sample materials; centrifuges for laboratory use; vacuum manifold and one or more membrane holders for filtration of liquids for laboratory use; scientific apparatus for laboratory use, namely, centrifugal vacuum concentrators designed to separate, concentrate, centrifuge and dry biological and chemical materials; rotors for laboratory centrifuges and vacuum concentrators and microtube mixers for laboratory use; mechanical, electronic and automatic pipettes and dispensers for dispensing liquid for laboratory research and analysis purposes ] | SECTION 71 - CANCELLED | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by QIAGEN GmbH
- Other trademarks owned by QIAGEN GmbH
- Other trademarks owned by QIAGEN GmbH
- Other trademarks in Class 001
- Other trademarks in Class 005
- Other trademarks in Class 009
- Similar marks named BISULFITOME
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Aug 16, 2021 | INNA | INVALIDATION REVIEWED - NO ACTION REQUIRED BY OFFICE | — |
| Aug 2, 2021 | INPR | PARTIAL INVALIDATION OF REG EXT PROTECTION CREATED | — |
| Dec 2, 2020 | NA71 | NOTICE OF ACCEPTANCE OF SEC. 71 - E-MAILED | — |
| Dec 2, 2020 | 71AG | REGISTERED-SEC.71 ACCEPTED | — |
| Nov 25, 2020 | APRE | CASE ASSIGNED TO POST REGISTRATION PARALEGAL | — |
| Jul 31, 2020 | ES71 | TEAS SECTION 71 RECEIVED | — |
| Aug 3, 2019 | REM4 | COURTESY REMINDER - SEC. 71 (10-YR) E-MAILED | — |
| Nov 22, 2018 | RNWL | INTERNATIONAL REGISTRATION RENEWED | — |
| Oct 18, 2018 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Jun 23, 2017 | INNP | PARTIAL INVALIDATION PROCESSED BY THE IB | — |
| May 4, 2017 | INPS | PARTIAL INVALIDATION OF REG EXT PROTECTION SENT TO IB | — |
| May 4, 2017 | INPC | INVALIDATION PROCESSED | — |
| Apr 29, 2017 | INPR | PARTIAL INVALIDATION OF REG EXT PROTECTION CREATED | — |
| Aug 29, 2016 | NA75 | NOTICE OF ACCEPTANCE OF SEC. 71 & 15 - E-MAILED | — |
| Aug 29, 2016 | C75P | REGISTERED - PARTIAL SEC. 71 ACCEPTED & SEC. 15 ACK. | — |
| Aug 25, 2016 | APRE | CASE ASSIGNED TO POST REGISTRATION PARALEGAL | — |
| Jul 19, 2016 | ES75 | TEAS SECTION 71 & 15 RECEIVED | — |
| Aug 22, 2014 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Jul 12, 2013 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Feb 12, 2013 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Nov 5, 2010 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Nov 5, 2010 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Nov 3, 2010 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Aug 3, 2010 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| May 18, 2010 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| May 18, 2010 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Apr 12, 2010 | PREV | LAW OFFICE PUBLICATION REVIEW COMPLETED | — |
| Apr 12, 2010 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Apr 10, 2010 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Apr 10, 2010 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Apr 10, 2010 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Apr 10, 2010 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Apr 6, 2010 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Apr 5, 2010 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Apr 5, 2010 | ERFR | TEAS REQUEST FOR RECONSIDERATION RECEIVED | — |
| Mar 5, 2010 | GNS1 | NOTIFICATION OF SUBSEQUENT FINAL EMAILED | — |
| Mar 5, 2010 | GNCF | CONTINUATION OF FINAL REFUSAL E-MAILED | — |
| Mar 5, 2010 | CNCF | ACTION CONTINUING A FINAL - COMPLETED | — |
| Feb 17, 2010 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Feb 17, 2010 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Feb 17, 2010 | ERFR | TEAS REQUEST FOR RECONSIDERATION RECEIVED | — |
| Aug 27, 2009 | GNFN | NOTIFICATION OF FINAL REFUSAL EMAILED | — |
| Aug 27, 2009 | GNFR | FINAL REFUSAL E-MAILED | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Aug 27, 2009 | CNFR | FINAL REFUSAL WRITTEN | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Aug 3, 2009 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Aug 3, 2009 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Aug 3, 2009 | ALIE | ASSIGNED TO LIE | — |
| Jul 16, 2009 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jul 14, 2009 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jul 14, 2009 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| May 15, 2009 | RFNT | REFUSAL PROCESSED BY IB | — |
| Apr 21, 2009 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Apr 21, 2009 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Apr 19, 2009 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Apr 18, 2009 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Apr 14, 2009 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Apr 10, 2009 | DOCK | ASSIGNED TO EXAMINER | — |
| Apr 10, 2009 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Apr 9, 2009 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |